[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.161.157.73. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Article
September 1, 1975

Methylene Blue for Eczema Herpeticum

Author Affiliations

Tufts University School of Medicine Boston

JAMA. 1975;233(9):987. doi:10.1001/jama.1975.03260090053028
Abstract

Eczema herpeticum has emerged as the most common form of Kaposi varicelliform eruption since the discontinuation of routine smallpox vaccination. It can be a serious complication of infantile eczema, with a death rate as high as 9%.1 Successful treatment with systemic administration of cytarabine has been reported, but the true value of this drug remains to be determined.2 Furthermore, cytarabine is not without toxic effects—notably bone marrow depression— after being administered systemically.

Methylene blue, a phenothiazine derivative, has been shown to be viricidally active toward herpesvirus hominis in the presence of light exposure, both in vitro3 and in vivo.4 The dye enters living cells, but transiently, thus inactivating both extracellular and intracellular viruses with minimal damage to the cells. Recently, a controlled study indicated methylene blue's therapeutic effectiveness in eczema herpeticum.5 Local application of 0.1% methylene blue solution to half of the diseased area followed

×